Somewhat Favorable News Coverage Somewhat Unlikely to Affect Epizyme (EPZM) Stock Price
Press coverage about Epizyme (NASDAQ:EPZM) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Epizyme earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.4703019824929 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Pre-Market Technical Scan on Biotech Equities — BioMarin Pharma, Aptevo Therapeutics, Otonomy, and Epizyme – PR Newswire (press release) (prnewswire.com)
- Epizyme (EPZM) Highlights Preclinical Data on Novel G9a Program … – StreetInsider.com (streetinsider.com)
- Epizyme (EPZM) Presents New Biomarker Data on Tazemetostat at ASH – StreetInsider.com (streetinsider.com)
- Comparing Epizyme (EPZM) and Nantkwest (NK) (americanbankingnews.com)
- EZM8266 is the First of Three New Compounds to be Named as Part of Epizyme’s Vision 2020 (globenewswire.com)
Shares of Epizyme (NASDAQ EPZM) opened at $12.70 on Monday. Epizyme has a twelve month low of $9.30 and a twelve month high of $20.45.
A number of research analysts recently commented on EPZM shares. Jefferies Group started coverage on Epizyme in a report on Wednesday, September 20th. They issued a “buy” rating and a $23.00 price target on the stock. Oppenheimer reissued a “buy” rating and issued a $26.00 price target on shares of Epizyme in a report on Tuesday, September 19th. Cann reissued a “buy” rating and issued a $26.00 price target on shares of Epizyme in a report on Tuesday, September 19th. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Monday, October 16th. Finally, Royal Bank of Canada reissued a “buy” rating and issued a $20.00 price target on shares of Epizyme in a report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $22.67.
In other news, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total transaction of $246,600.00. Following the sale, the insider now directly owns 23,123 shares of the company’s stock, valued at approximately $380,142.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 25.20% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-epizyme-epzm-stock-price/1770739.html.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.